Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform and raises the price target from $50 to $56.
Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform and raises the price target from $50 to $56.